AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

February 1, 2027

Conditions

Efficacy

Interventions

DRUG

PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy

PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.

All Listed Sponsors

lead

Hunan Province Tumor Hospital

OTHER

NCT06196814 - AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC | Biotech Hunter | Biotech Hunter